Sertraline for social anxiety disorder

References

• Greenberg PE, Sisitsky T, Kessler RC eta! The economic burden of anxiety disorders in the 1990.1 Clin. Psychiatry60, 427–430 (1999).
   Google Scholar
• Lepine JR The Epidemiology of anxiety disorders: prevalence and societal costs. Clin. PTchiatry63\(Suppl. 14), 4–8 (2002).
   Google Scholar
• Kessler RC, McGonagle IKA, Zhao S eta]. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51,8–19 (1994).
   Google Scholar
• •Classic article on the prevalence of anxiety disorders.
   Google Scholar
• Diagnostic and Statistical Manual of Mental Dismrlers. Fourth Edition. American Psychiatric Association, Washington DC, USA (1994).
   Google Scholar
• World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorrlers: Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva, Switzerland (1992).
   Google Scholar
• Kessler RC, Stein MB, Berglund PA. Social phobia subtypes in the National Comorbidity Survey. Ainj PTchiatry155, 613–619 (1998).
   Google Scholar
• Katzelnik DJ, Greist JH. Social anxiety disorder: an unrecognized problem in primary care. I Clin. Fiychiatry62 (Suppl. 11), 11–15 (2001).
   Google Scholar
• Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings. Am. I Psychiatry 157(10), 1606–1613 (2000).
   PubMed Web of Science ®Google Scholar
• Katzelnick DJ, Kobak KA, DeLeire T et al. impact of generalized social anxiety disorder in managed care. Am. I Psychiatry 158(12), 1999–2007 (2001).
   PubMed Web of Science ®Google Scholar
• Lydiard RB. social anxiety disorder: comorbidity and its implications. J. Clin. Psychiatry 62\(Suppl. 1), 17–25 (2001).
   Google Scholar
• Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiological sample. Arch. Gen. Psychiatry49,282–288 (1992).
   Google Scholar
• Kessler RC, Stang P, Wittchen H-U, Stein MB, Walters EE. Lifetime comorbidities between social phobia and mood disorders in the US National Comorbidity Survey. Psycho" Med. 29, 555–567 (1999).
   Google Scholar
• Pini S, Cassano GB, Simonini E, Savino M, Russo A, Montgomery SA. Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. I Affect. Disord 42,145–153 (1997).
   PubMed Web of Science ®Google Scholar
• Stein MB, Chavira DA. Subtypes of social phobia and comorbidity with depression and other anxiety disorders. I Affect. Disord 50,511—S16 (1998).
   Web of Science ®Google Scholar
• Coupland NJ. Social phobia: etiology, neurobiology and treatment. I Clin. Psychiatry62 (Suppl. 1), 25–35 (2001).
   Google Scholar
• Bell CJ, Malizia AL, Nutt DJ. The neurobiology of social phobia. Eur. Neuropsychopharmacol 8,311–313 (1998).
   PubMed Web of Science ®Google Scholar
• Pollack MET. Comorbidity, neurobiology and pharmacotherapy of social anxiety disorder. I Clin. Psychiatry62\(Suppl. 12), 24–30 (2001).
   Google Scholar
• Schneier FR, Michael R, Liebowitz, Abi- Dargham A eta! Low dopamine D2 receptor binding potential in social phobia. AIR I fiychiatry157(3), 457–459 (2000).
   Google Scholar
• Stein DJ, Westenberg HGM, Liebowitz MR. Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. I Clin. PTchiatry63\(Suppl. 6), 12–19 (2002).
   Google Scholar
• Mathew SJ, Coplan JD, Jack M. Gorman JM. Neurobiological mechanisms of social anxiety disorder. Am. I PTchiatry158(10), 1558–1567 (2001).
   Google Scholar
• ••Review.
   Google Scholar
• Otto MW, Pollack MET, Gould RA, Worthington JJ 3rd, McArdle ET, Rosenbaum JE A comparison of clonazepam and cognitive—behavioral group therapy for the treatment of social phobia. Anxiety Dir. 14,345–358 (2000).
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Heimberg RG, Schneier FR et al Cognitive—behavioral group therapy versus phenelzine in social phobia:long-term outcome. Depress. Anxiety10,89–98 (1999).
   PubMed Web of Science ®Google Scholar
• Radomsky A, Otto MW. Cognitive— behavioral therapy for the treatment of social anxiety disorder. Bychiatr Clin. North Am. 24,805–815 (2001).
   PubMed Web of Science ®Google Scholar
• Shear MK, Beidel DC. Psychotherapy in the overall management strategy for social anxiety disorder. I Clin. Psychiatry 59\(Suppl. 17), 39–46 (1998).
   Google Scholar
• Otto MW. Cognitive—behavioral therapy for social anxiety disorder: model, methods and outcome. I Clin. Psychiatry60\(Suppl. 9), 14–19 (1999).
   Google Scholar
• Blomhoff S, Haug TT, Hellstrom K et al Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br. Psychiatry179 (7), 23–30 (2001).
   PubMed Web of Science ®Google Scholar
• Haug TT, Blomhoff S, Hellstrom K eta! Exposure therapy and sertraline in social phobia: 1 year follow-up of a randomised controlled trial. BE j Psychiatry182(4), 312–318 (2003).
   Google Scholar
• Schneier FR. Treatment of social phobia with antidepressants. J. Clin. Psychiatry 62 (Suppl. 1), 43–49 (2001).
   Google Scholar
• Jefferson JW. Benzodiazepines and anticonvulsants for social phobia. J. Clin. Ptychiatry62\(Suppl. 1), 50–53 (2001).
   Google Scholar
• Schatzberg AF New indications for antidepressants. J. Clin. Bychiatry 61 (Suppl. 11), 9–17 (2000).
   Google Scholar
• Van Ameringen MA, Mancini C, Farvolden P, Oakman J. Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. Expert Opin. Investig Drugs. 9(10), 2215–2231 (2000).
   Google Scholar
• Nardi AE. Antidepressants in social anxiety disorder. Arq. Neuropsiquiatr 59(3A), 637–642 (2001).
   Google Scholar
• Van Ameringen MA, Mancini C, Oakman JM, Farvolden P. Selective serotonin re-uptake inhibitors in the treatment of social phobia. The emerging gold standard. CNS DITIF 11(4), 307–315 (1999).
   Web of Science ®Google Scholar
• Richelson E. Pharmacology of antidepressants. Mayo Clin. Proc. 76,511–527 (2001).
   PubMed Web of Science ®Google Scholar
• MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Thug Rev 7 (1), 1–24 (2001).
   PubMedGoogle Scholar
• •• Comprehensive review.
   Google Scholar
• DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin. Pharmacokinet. 41(15), 1247–1266 (2002).
   Google Scholar
• •• Review.
   Google Scholar
• Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int. Clin. Psychopharmacology 9 (Suppl. 3), 13–19 (1994).
   Google Scholar
• Baumann P Pharmacolkinetic — pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Gun Phatmacokinet. 31(6), 444–469 (1996).
   Google Scholar
• Alderman J, Wolkow R, Chung M, Johnston HE Sertraline treatment of children and adolescents with obsessive—compulsive disorder or depression: pharmacokinetics, tolerability and efficacy. Am. Acad. Child. Adolesc. Psychiatry 37(4), 386–394 (2001).
   Google Scholar
• Axelson DA, Perel JM, Birmaher B etal. Sertraline pharmacokinetics and dynamics in adolescents. jAm. Acad. Child. Adolesc fiychiatry41 (9), 1037–1044 (2002).
   Google Scholar
• Zoloft® (sertraline) product monograph. Pfizer, MI, USA
   Google Scholar
• Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy19(7), 894–896 (1999).
   PubMed Web of Science ®Google Scholar
• Markowitz JS, DeVaneCL. Rifampin- induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. j Clin. fiychophatmacol 20,109–110 (2000).
   PubMed Web of Science ®Google Scholar
• Pihlsgard M, Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. Eur j Clin. Pharmacol 57(12), 915–916 (2002).
   Web of Science ®Google Scholar
• Hoehns JD, Fouts MM, Kelly MW Tu KB. Sudden cardiac death with clozapine and sertraline combination. Ann. Pharmacother 35(7–8), 862–866 (2001).
   Google Scholar
• Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline and paroxetine in healthy volunteers. Comprehensive review. J. Clin. fiychophatmacol 22(2), 169–173 (2002).
   Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug—drug interactions: an update. CI.117: Drug- Metab. 3(1), 13–37 (2002).
   Google Scholar
• •• Comprehensive review.
   Google Scholar
• Van Ameringen M, Mancini C, Streiner D. Sertraline in social phobia. J. Affect. Disond 31(2), 141–145 (1994)
   Google Scholar
• Munjack DJ, Flowers C, Eagan TV. Sertraline in social phobia. Anxietyl (4), 196–198 (1994–95).
   Google Scholar
• Czepowicz VD, Johnson MR, Lydiard RB eta]. Sertraline in social phobia. J. Clin. fiychophatmacol 15(5), 372–373, (1995)
   Google Scholar
• Martins EA, Pigott TA, Bernstein SE et al Sertraline in the treatment of patients with social phobia. A n xi ety1(6), 291–297 (1994–95).
   Google Scholar
• Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS. Sertraline in children and adolescents with social anxiety disorder: an open trial. J. Am. Acad. Child. Adolesc. Psychiatry 40(5), 564–571 (2001).
   Google Scholar
• Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am. J. fiychiatry152(9), 1368–1371 (1995).
   Google Scholar
• •Double-blind controlled study.
   Google Scholar
• Van Ameringen MA, Lane RM, Walker JR, Bowen RC eta! Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158(2), 275–281 (2001).
   Google Scholar
• •Double-blind controlled study.
   Google Scholar
• Liebowitz MR, DeMartinis N, Weihs K et al Efficacy of sertraline in severe generalized anxiety disorder: results of a double-blind Placebo-controlled study. Personal communication with Pfizer, (Spring 2003).
   Google Scholar
• Walker JR, Van Ameringen MA, Swinson R et al Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. j Clin. Bychopharmacol 20(6), 636–644 (2000).
   Google Scholar
• •Comprehensive review.
   Google Scholar
• Blomhoff S, Haug TT, Hellstrom K eta! Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br. Psychiatry179(7), 23–30 (2001).
   PubMed Web of Science ®Google Scholar
• Goodnick PJ, Jerry J, Parra E Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin. Pharmacother. 3(5), 479–498 (2002).
   Google Scholar
• Wilens TE, Biederman J, March JS et al Absence of cardiovascular adverse effects of sertraline in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 38(5), 573–577 (1999).
   Google Scholar
• Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and economics. J. Psychopharmaco1.12\(Suppl. 1), 43–49 (1998).
   Google Scholar
• Murphy TK, Bengtson MA, Tan JY, Carbonell E, Levin GM. Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review. Int. Clin. 13ychophannacol 15\(Suppl. 2), S47—S63 (2000).
   Google Scholar
• Rynn MA, Siqueland L, Rickels K. Placebo- controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am. J. Ptychiatry158(12), 2008-2014 (2001).
   Google Scholar
• Findling RL, Reed MD, Blumer JL. Pharmacological treatment of depression in children and adolescents. Paecliatr Drugs 1(3), 161–182 (1999).
   PubMedGoogle Scholar
• Cook EH, Wagner KD, March JS et al Long-term sertraline treatment of children and adolescents with obsessive—compulsive disorder. jAm. Acad. Child. Adolesc Psychiatry40(10), 1175–1181 (2001).
   Google Scholar
• March JS, Biederman J, Wolkow R eta! Sertraline in children and adolescents with obsessive—compulsive disorder: a multicentre randomized controlled trial JAIVIA 280(20), 1752–1756 (1998).
   Google Scholar
• Nixon MK, Milin R, Simeon JG, Cloutier P, Spenst W Sertraline effects in adolescent major depression and dysthymia: a 6 month open trial. j Child Adolesc. Bychopharmacol 11(2), 131–142 (2001).
   Google Scholar
• Fava M. Weight gain and antidepressants. J. Clin. Psychiatry61\(Suppl. 11), 41–47 (2000).
   Google Scholar
• Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J. Clin. PTchiatry62\(Suppl. 3), 22–34 (2001).
   Google Scholar
• Montejo AL, Llorca G, Izquierdo JA, Rico- Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry 62 (Suppl. 3), 10–21 (2001).
   Google Scholar
• Fartoux-Heymann L, Hezode C, Zafrani ES, Dhumeaux D, Mallat A. Acute fatal hepatitis related to sertraline. I Hepatol 35(5), 683–684 (2001).
   Web of Science ®Google Scholar
• Spigset 0, Hagg S, Bate A. A hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int. Clin. Psychopharm. 18 (3), 157–161 (2003).
   Google Scholar
• Persky S, Reims JE Sertraline hepatotoxicity: A case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig. Dc. 48 (5), 934–944 (2003).
   Web of Science ®Google Scholar
• Carvajal GP, Garcia D, Sanchez SA, Velasco MA, Rueda D, Lucena MI. Hepatotoxicity associated with the new antidepressants. J. Clin. Psychiatry 64 (2), 135–137 (2002)
   Google Scholar
• Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern. Med. 163(1), 59–64 (2003).
   Web of Science ®Google Scholar
• Bak S, Tsiropoulos I, Kjaersgaard JO eta! Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 33(6), 1465–1473 (2002).
   PubMed Web of Science ®Google Scholar
• Layton D, Clark DW, Pearce GL, Shakir SA. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur. j Clin. Pharmacol 57(2), 167–176 (2001).
   Google Scholar
• Lake MB, Birmaher B, Wassick S, Mathos K, Yelovich AK. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J. Child Adolesc. PTchopharmacol 10(1), 35–38 (2000).
   Google Scholar
• Klein-Schwartz W Anderson B. Analysis of the sertraline only overdose. Am. J. Emerg. Med. 14,456-458 (1996).
   Google Scholar
• Kuhn NA, Pastuszak A, Sage SR eta]. Pregnancy outcome following maternal use of the new selective serotonin re-uptake inhibitors: a prospective controlled multicenter study. JAIVIA 279(8), 609–610 (1998).
   PubMed Web of Science ®Google Scholar
• Wilton LW, Pearch YL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. BE I Obstet. Cynacol 105,882–889.
   Google Scholar
• Stowe ZN, Hostetter AL, Owens MJ eta! The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. I Clin. Psychiatry 64 (1), 73–80 (2003).
   Google Scholar
• Epperson N, Czarkowski KA, Ward-O'Brien D eta]. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am. J. PTchiatry158(10), 1631–1637 (2001).
   Google Scholar
• Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. BE J. PTchiatry179,163–166 (2001).
   PubMed Web of Science ®Google Scholar
• Kristensen JH, Ilett KF, Dusci LJ et al Distribution and excretion of sertraline and N-desmethylsertraline in human milk. BE Clin. Pharmacol 45(5), 453–457 (1998).
   Web of Science ®Google Scholar
• Wisner KL, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother—infant pairs. Am. I fiychiatry 155 (5), 690–692 (1998).
   Google Scholar
• Gallenger JC, Davidson JR, Lecruiber Y eta]. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. PTchiatry59\(Suppl. 17), 54–80 (1998).
   Google Scholar
• Anxiety Review Panel. Evans M, Bradwejn J, Dunn L (Eds). Ontario Guidelines for the Management of Anxiety Disorders in Primary Care. Queen's Printer of Ontario, Toronto, Canada (2002).
   Google Scholar